🔎 Trials Near Me

Utama › Kanser Paru-paru › Michigan

Kajian klinikal Kanser Paru-paru di Michigan

44 kajian untuk Kanser Paru-paru sedang mencari peserta di lokasi di Michigan.

Bandar di Michigan

Teks kajian rasmi (Bahasa Inggeris)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • Bronson Battle Creek, Battle Creek
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • dan 50 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT04267848

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • MyMichigan Medical Center Gratiot, Alma
  • MyMichigan Medical Center Alpena, Alpena
  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • dan 68 lagi
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

  • Bronson Battle Creek, Battle Creek
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
  • dan 20 lagi
Mengambil pesertaFasa 3
Umur 70 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06096844

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health Medical Center - Brighton, Brighton
  • dan 27 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT04181060

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  • University of Michigan Rogel Cancer Center, Ann Arbor
  • Bronson Battle Creek, Battle Creek
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • dan 38 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06498635

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  • Trinity Health Ann Arbor Hospital, Ann Arbor
  • Karmanos Cancer Institute, Detroit
  • Henry Ford Health, Detroit
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT06881784

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  • Corewell Health - Butterworth Hospital, Grand Rapids
  • Corewell Health - Lemmen Holton Cancer Pavilion, Grand Rapids
  • Corewell Health - Research Specimen Processing Area, Grand Rapids
  • dan 2 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06758401

A Registry for People With Lung Cancer

  • University of Michigan (Data Collection Only), Ann Arbor
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06424327

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  • Local Institution - 0418, Ann Arbor
  • Local Institution - 0405, Detroit
  • Local Institution - 0420, Traverse City
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07063745

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  • START Midwest, Grand Rapids
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06128551

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

  • University of Michigan Medical School Rogel Cancer Center, Ann Arbor
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Sep 2026 · NCT07629960

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

  • START Midwest, Grand Rapids
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Sep 2026 · NCT07349537

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

  • South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT05786924

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

  • Karmanos Cancer Institiute, Detroit
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Sep 2026 · NCT06293898

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • University of Michigan, Ann Arbor
  • The Cancer & Hematology Centers, Grand Rapids
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT06119581

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

  • South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Sep 2026 · NCT06400472

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

  • Henry Ford Cancer - Detroit, Detroit
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06343402

The Vanguard Study: Testing a New Way to Screen for Cancer

  • Henry Ford Cancer Institute-Downriver, Brownstown
  • Henry Ford Health Center - Brownstown, Brownstown
  • Henry Ford Health Center - Chesterfield, Chesterfield
  • dan 13 lagi
Mengambil pesertaSukarelawan sihat dialu-alukan
Umur 45 hingga 75 · Semua jantina · Dikemas kini 2 Sep 2026 · NCT06995898

Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung

  • University of Michigan, Ann Arbor
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT07499674

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

  • Wayne State University/Karmanos Cancer Institute, Detroit
  • Weisberg Cancer Treatment Center, Farmington Hills
  • McLaren Cancer Institute-Flint, Flint
  • dan 1 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT06500481

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • McLaren Cancer Institute-Bay City, Bay City
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • dan 41 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT05624996

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

  • Karmanos Cancer Institute, Detroit
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Ogo 2026 · NCT05592626

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

  • START - Midwest, Grand Rapids
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Ogo 2026 · NCT07444814

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

  • Henry Ford Cancer Institute, Detroit
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Jul 2026 · NCT04198766

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

  • Henry Ford Cancer- Detroit, Detroit
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Jul 2026 · NCT07339059

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

  • Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Jun 2026 · NCT06162221

Gilteritinib for the Treatment of ALK NSCLC

  • University of Michigan Comprehensive Cancer Center, Ann Arbor
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 26 Jun 2026 · NCT06225427

Prediction Augmented Screening Initiative

  • VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
Mengambil peserta
Umur 50 hingga 80 · Semua jantina · Dikemas kini 26 Jun 2026 · NCT06538636

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

  • Karmanos Cancer Institute, Detroit
Mengambil pesertaFasa 2
Umur 18 hingga 70 · Semua jantina · Dikemas kini 26 Jun 2026 · NCT04614103

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health Medical Center - Brighton, Brighton
  • dan 19 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Jun 2026 · NCT05642572

A Study of ZW251 in Participants With Advanced Solid Tumors

  • START Midwest, Grand Rapids
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Mei 2026 · NCT07164313

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health Medical Center - Brighton, Brighton
  • dan 14 lagi
Mengambil pesertaFasa 2
18 Minutes · Semua jantina · Dikemas kini 5 Mei 2026 · NCT06031688

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
  • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
  • dan 7 lagi
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Mei 2026 · NCT06616584

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

  • University of Michigan, Ann Arbor
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Apr 2026 · NCT07020221

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

  • Karmanos Cancer Institute, Detroit
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Mac 2026 · NCT06244771

Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy

  • VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Feb 2026 · NCT02984761

EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

  • VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Jan 2026 · NCT05467748

A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients

  • University of Michigan Comprehensive Cancer Center, Ann Arbor
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Jan 2026 · NCT07291414

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.